{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unmethylated+Glioblastoma&page=2",
    "query": {
      "condition": "Unmethylated Glioblastoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Unmethylated+Glioblastoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:02:23.423Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03367715",
      "title": "Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MGMT-unmethylated Glioblastoma (GBM)",
        "GBM"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy (RT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-02-07",
      "completion_date": "2022-03-17",
      "has_results": true,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03367715"
    },
    {
      "nct_id": "NCT00813943",
      "title": "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Cilengitide (2-times weekly)",
          "type": "DRUG"
        },
        {
          "name": "cilengitide (5-times weekly)",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2009-03",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00813943"
    },
    {
      "nct_id": "NCT06504381",
      "title": "DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "MGMT-Unmethylated Glioblastoma",
        "MGMT-Methylated Glioblastoma"
      ],
      "interventions": [
        {
          "name": "DB107-RRV",
          "type": "GENETIC"
        },
        {
          "name": "DB107-FC",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy (RT)",
          "type": "RADIATION"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging (MRI)",
          "type": "PROCEDURE"
        },
        {
          "name": "Surgical resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2025-01-08",
      "completion_date": "2042-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06504381"
    },
    {
      "nct_id": "NCT05283109",
      "title": "ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiltonol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-08-30",
      "completion_date": "2028-02-28",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283109"
    },
    {
      "nct_id": "NCT03522298",
      "title": "Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma, Adult"
      ],
      "interventions": [
        {
          "name": "Paxalisib (GDC-0084)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kazia Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-05-15",
      "completion_date": "2023-03-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03522298"
    },
    {
      "nct_id": "NCT04015700",
      "title": "Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CELLECTRA®2000 EP Device supplied by Geneos Therapeutics",
          "type": "DEVICE"
        },
        {
          "name": "Plasmid encoded IL-12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-07-14",
      "completion_date": "2027-09-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04015700"
    },
    {
      "nct_id": "NCT06388733",
      "title": "A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma",
        "GBM",
        "Brain Neoplasms, Adult, Malignant",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ivy Brain Tumor Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2024-06-19",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Guilford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06388733"
    },
    {
      "nct_id": "NCT03107780",
      "title": "Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma",
        "MGMT-Unmethylated Glioblastoma",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Navtemadlin",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2018-07-09",
      "completion_date": "2025-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03107780"
    },
    {
      "nct_id": "NCT06973096",
      "title": "CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "CART-EGFR-IL13Ra2 cells",
          "type": "DRUG"
        },
        {
          "name": "Rituximab or Rituximab biosimilar",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine + Cyclophosphamide combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2025-07-18",
      "completion_date": "2042-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06973096"
    },
    {
      "nct_id": "NCT06359379",
      "title": "Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma, IDH-wildtype"
      ],
      "interventions": [
        {
          "name": "Ropidoxuridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shuttle Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-09-02",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-05-22T04:02:23.423Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06359379"
    }
  ]
}